Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 und 5. 1 für verfügbare daten zu verschiedenen kombinationen).

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 und 5. 1 für verfügbare daten zu verschiedenen kombinationen).

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin-hydrochlorid - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - olopatadinhydrochlorid - konjunktivitis, allergisch - ophthalmika - behandlung von augenzeichen und symptomen der saisonalen allergischen konjunktivitis.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunsuppressiva - simulect ist indiziert zur prophylaxe bei akuter abstoßungsreaktionen in de-novo allogene nierentransplantation bei erwachsenen und pädiatrischen patienten (1-17 jahre). es ist zu sein verwendet in verbindung mit für ciclosporin mikroemulsion und kortikosteroiden basierenden immunsuppression bei patienten mit panel-reaktive antikörper, die weniger als 80%, oder in einem dreifach-wartung immunsuppressive therapie mit ciclosporin mikroemulsion für, kortikosteroiden und entweder azathioprin oder mycophenolatmofetil.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - nateglinid - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - nateglinid ist indiziert für die kombinationstherapie mit metformin bei typ-2-diabetikern, die trotz einer maximal tolerierten dosis von metformin allein nicht ausreichend kontrolliert werden.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 und 5. 1 für verfügbare daten zu verschiedenen kombinationen).

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - senkung des erhöhten augeninnendrucks bei erwachsenen patienten mit okulärer hypertension oder offenwinkelglaukom (siehe abschnitt 5). senkung des erhöhten augeninnendrucks bei pädiatrischen patienten im alter von 3 jahre bis < 18 jahre mit okulärer hypertension oder pädiatrische glaukom.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

novartis europharm limited - nepafenac - pain, postoperative; ophthalmologic surgical procedures - ophthalmika - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.